CanSino Biologics Inc
SSE:688185

Watchlist Manager
CanSino Biologics Inc Logo
CanSino Biologics Inc
SSE:688185
Watchlist
Price: 60.21 CNY -1.67% Market Closed
Market Cap: 6.9B CNY
Have any thoughts about
CanSino Biologics Inc?
Write Note

CanSino Biologics Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CanSino Biologics Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
CanSino Biologics Inc
SSE:688185
Interest Income Expense
ÂĄ115.1m
CAGR 3-Years
119%
CAGR 5-Years
229%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
ÂĄ1.1B
CAGR 3-Years
52%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
ÂĄ145.3m
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
ÂĄ472.8m
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
ÂĄ958.5m
CAGR 3-Years
-5%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
-ÂĄ20.1m
CAGR 3-Years
-107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CanSino Biologics Inc
Glance View

Market Cap
6.9B CNY
Industry
Pharmaceuticals

CanSino Biologics Inc is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 1,946 full-time employees. The company went IPO on 2019-03-28. CanSino Biologics Inc is a clinical-stage vaccine company in China. The firm's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Intrinsic Value
100.3 CNY
Undervaluation 40%
Intrinsic Value
Price

See Also

What is CanSino Biologics Inc's Interest Income Expense?
Interest Income Expense
115.1m CNY

Based on the financial report for Dec 31, 2023, CanSino Biologics Inc's Interest Income Expense amounts to 115.1m CNY.

What is CanSino Biologics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
229%

Over the last year, the Interest Income Expense growth was -58%. The average annual Interest Income Expense growth rates for CanSino Biologics Inc have been 119% over the past three years , 229% over the past five years .

Back to Top